Breast cancer eradication program

Abstract

A method of treating breast cancer that is at least partially ER + is disclosed. The method comprises administering at a tumor site in a mammalian subject a pharmaceutically acceptable form of Fe(II) or Fe(III) in a suitable carrier. A four-part program aimed at eradicating breast cancer includes (a) local treatment and prevention of spread from a contained breast site, preferably using local administration of a ferric iron composition, (b) treatment of disseminated (metastatic) breast cancer, (c) reduction in the risk of developing breast cancer, preferably by enhancing dimeric/polymeric IgA and polymeric IgM inhibition of estrogen responsive cell growth, and (d) protection against cancer causing agents.

1 - 31 . (canceled) 
     
     
         32 . A method of treating ER +  breast cancer comprising administering an immunogen, wherein the immunogen causes an increase in the number of IgA or IgM secreting B lymphocytes in breast tissue. 
     
     
         33 . The method of  claim 32 , wherein both IgA secreting B lymphocytes and IgM secreting B lymphocytes increase in number. 
     
     
         34 . The method of  claim 32 , wherein the immunogen is administered orally, nasally, rectally, or by vaginal challenge. 
     
     
         35 . The method of  claim 34 , wherein the immunogen is administered orally. 
     
     
         36 . The method of  claim 35 , wherein the immunogen is in the form of a tablet, food product, or food drink. 
     
     
         37 . The method of  claim 32  further comprising administering IgA, IgM, Fc fragments of IgA, Fc fragments of IgM, or combinations thereof. 
     
     
         38 . The method of  claim 32  further comprising administering tamoxifen. 
     
     
         39 . The method of  claim 32 , wherein the immunogen is administered to a subject during puberty. 
     
     
         40 . The method of  claim 32 , wherein the immunogen is administered to a subject after menopause. 
     
     
         41 . The method of  claim 32 , wherein the immunogen is bacteria or a bacterial component. 
     
     
         42 . The method of  claim 41 , wherein the bacteria is  Escherichia coli.    
     
     
         43 . The method of  claim 42 , wherein the bacterial component is derived from  E. coli.    
     
     
         44 . The method of  claim 41 , wherein the bacteria is live. 
     
     
         45 . The method of  claim 41 , wherein the bacteria is attenuated. 
     
     
         46 . The method of  claim 32 , wherein the immunogen causes an increase in inhibitory immunoglobulins. 
     
     
         47 . A method of treating ER +  breast cancer comprising administering IgA, IgM, Fc fragments of IgA, Fc fragments of IgM, or combinations thereof. 
     
     
         48 . The method of  claim 36 , wherein the food product is genetically modified.